xCT (Slc7a11), the specific subunit of the cystine/glutamate antiporter system x, is present in the brain and on immune cells, where it is known to modulate behavior and inflammatory responses. In a variety of cancers -including pancreatic ductal adenocarcinoma (PDAC)-, xCT is upregulated by tumor cells to support their growth and spread. Therefore, we studied the impact of xCT deletion in pancreatic tumor cells (Panc02) and/or the host (xCT mice) on tumor burden, inflammation, cachexia and mood disturbances.
View Article and Find Full Text PDFThe cystine/glutamate antiporter system x has been identified as the major source of extracellular glutamate in several brain regions as well as a modulator of neuroinflammation, and genetic deletion of its specific subunit xCT (xCT) is protective in mouse models for age-related neurological disorders. However, the previously observed oxidative shift in the plasma cystine/cysteine ratio of adult xCT mice led to the hypothesis that system x deletion would negatively affect life- and healthspan. Still, till now the role of system x in physiological aging remains unexplored.
View Article and Find Full Text PDFThe astrocytic cystine/glutamate antiporter system x (with xCT as the specific subunit) imports cystine in exchange for glutamate and has been shown to interact with multiple pathways in the brain that are dysregulated in age-related neurological disorders, including glutamate homeostasis, redox balance, and neuroinflammation. In the current study, we investigated the effect of genetic xCT deletion on lactacystin (LAC)- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced degeneration of the nigrostriatal pathway, as models for Parkinson's disease (PD). Dopaminergic neurons of adult xCT knock-out mice (xCT) demonstrated an equal susceptibility to intranigral injection of the proteasome inhibitor LAC, as their wild-type (xCT) littermates.
View Article and Find Full Text PDFDespite ample evidence for the therapeutic potential of inhibition of the cystine/glutamate antiporter system x in neurological disorders and in cancer, none of the proposed inhibitors is selective. In this context, a lot of research has been performed using the EMA- and FDA-approved drug sulfasalazine (SAS). Even though this molecule is already on the market for decades as an anti-inflammatory drug, serious side effects due to its use have been reported.
View Article and Find Full Text PDFThe astrocytic cystine/glutamate antiporter system x represents an important source of extracellular glutamate in the central nervous system, with potential impact on excitatory neurotransmission. Yet, its function and importance in brain physiology remain incompletely understood. Employing slice electrophysiology and mice with a genetic deletion of the specific subunit of system x, xCT (xCT mice), we uncovered decreased neurotransmission at corticostriatal synapses.
View Article and Find Full Text PDF